Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.
投資一家能夠扭轉命運的公司的興奮感對一些投機者來說是一個很大的吸引力,因此,即使是沒有收入、沒有利潤、有虧損記錄的公司,也可以設法找到投資者。有時,這些故事可能會使投資者的頭腦蒙上陰影,導致他們用自己的情感進行投資,而不是憑藉良好的公司基本面的優點進行投資。虧損公司可以像海綿一樣充當資本的海綿——因此投資者應謹慎行事,不要在壞錢之後投入好錢。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Xiamen Amoytop Biotech (SHSE:688278). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.
如果這種公司不是你的風格,你喜歡創收甚至盈利的公司,那麼你很可能會對廈門天拓生物科技(SHSE: 688278)感興趣。儘管利潤不是投資時應考慮的唯一指標,但值得認可能夠持續實現利潤的企業。
View our latest analysis for Xiamen Amoytop Biotech
查看我們對廈門愛摩拓生物科技的最新分析
Xiamen Amoytop Biotech's Improving Profits
廈門愛摩拓生物科技的利潤不斷提高
Over the last three years, Xiamen Amoytop Biotech has grown earnings per share (EPS) at as impressive rate from a relatively low point, resulting in a three year percentage growth rate that isn't particularly indicative of expected future performance. Thus, it makes sense to focus on more recent growth rates, instead. In impressive fashion, Xiamen Amoytop Biotech's EPS grew from CN¥0.63 to CN¥1.12, over the previous 12 months. It's not often a company can achieve year-on-year growth of 77%. The best case scenario? That the business has hit a true inflection point.
在過去三年中,廈門Amoytop Biotech的每股收益(EPS)從相對較低的水平增長了同樣可觀的速度,因此三年的百分比增長率並不能特別表明未來的預期表現。因此,改爲關注最近的增長率是有意義的。在過去的12個月中,廈門愛摩拓生物科技的每股收益從0.63元人民幣增長至1.12元人民幣,令人印象深刻。公司很少能實現77%的同比增長。最好的情況?業務已經到了真正的轉折點。
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Xiamen Amoytop Biotech shareholders can take confidence from the fact that EBIT margins are up from 23% to 29%, and revenue is growing. Both of which are great metrics to check off for potential growth.
收入增長是一個很好的指標,表明增長是可持續的,再加上較高的息稅前收益(EBIT)利潤率,這是公司保持市場競爭優勢的好方法。廈門Amoytop Biotech的股東可以從息稅前利潤率從23%上升到29%,收入也在增長這一事實中獲得信心。這兩個都是衡量潛在增長的好指標。
The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.
下圖顯示了該公司的收入和收入隨着時間的推移是如何發展的。要查看實際數字,請單擊圖表。
![earnings-and-revenue-history](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231212/0-e9a71bbb167932d2498d8eb5013fac4b-0-f09a27f4bc38e461474233416bee926b.png/big)
While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check Xiamen Amoytop Biotech's balance sheet strength, before getting too excited.
儘管看到利潤增長總是件好事,但你應該永遠記住,資產負債表疲軟可能會再次受到影響。因此,在太興奮之前,先看看廈門愛摩拓生物科技的資產負債表實力。
Are Xiamen Amoytop Biotech Insiders Aligned With All Shareholders?
廈門Amoytop Biotech內部人士是否與所有股東保持一致?
Many consider high insider ownership to be a strong sign of alignment between the leaders of a company and the ordinary shareholders. So as you can imagine, the fact that Xiamen Amoytop Biotech insiders own a significant number of shares certainly is appealing. In fact, they own 52% of the company, so they will share in the same delights and challenges experienced by the ordinary shareholders. This should be seen as a good thing, as it means insiders have a personal interest in delivering the best outcomes for shareholders. CN¥11b This is an incredible endorsement from them.
許多人認爲,高內幕所有權是公司領導人和普通股東保持一致的有力標誌。因此,你可以想象,廈門Amoytop Biotech內部人士擁有大量股票這一事實無疑很有吸引力。實際上,他們擁有公司52%的股份,因此他們將享受與普通股東相同的樂趣和挑戰。這應該被視爲一件好事,因爲這意味着爲股東提供最佳業績符合內部人士的個人利益。CN¥11b 這是他們的難以置信的認可。
Should You Add Xiamen Amoytop Biotech To Your Watchlist?
你應該將廈門愛摩拓生物科技添加到你的關注列表嗎?
Xiamen Amoytop Biotech's earnings have taken off in quite an impressive fashion. That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. At times fast EPS growth is a sign the business has reached an inflection point, so there's a potential opportunity to be had here. So based on this quick analysis, we do think it's worth considering Xiamen Amoytop Biotech for a spot on your watchlist. However, before you get too excited we've discovered 1 warning sign for Xiamen Amoytop Biotech that you should be aware of.
廈門Amoytop Biotech的收益以令人印象深刻的方式增長。這種增長簡直引人注目,內部人士持有的巨額投資無疑應該會讓公司的視野更加光明。有時,每股收益的快速增長表明業務已經到了轉折點,因此這裏有潛在的機會。因此,根據這個快速分析,我們確實認爲值得考慮將廈門愛摩拓生物技術放在你的關注名單上的一席之地。但是,在你太興奮之前,我們已經發現了廈門愛摩拓生物科技的1個警告信號,你應該注意。
The beauty of investing is that you can invest in almost any company you want. But if you prefer to focus on stocks that have demonstrated insider buying, here is a list of companies with insider buying in the last three months.
投資的好處在於,你幾乎可以投資任何你想要的公司。但是,如果你更喜歡關注表現出內幕買入的股票,以下是過去三個月內進行內幕買入的公司名單。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文中討論的內幕交易是指相關司法管轄區內應報告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。